Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Volume 376, Issue 9753, Pages (November 2010)

NICE –CG 181 Continuum of CVD Risk and its treatment

Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.

Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.

Brief pain inventory. (Reproduced with permission from the University of Texas MD Anderson Cancer Center, Department of Symptom Research, Houston, TX.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

A. Mechanism of action of aspirin

Algorithm for guideline-directed medical therapy for patients with stable ischemic heart disease. The use of bile acid sequestrant is relatively contraindicated.

Risk designation of full-term and near-term newborns based on their hour-specific bilirubin values. (Reproduced, with permission, from Bhutani VK et al:

APTT, activated partial thromboplastin time; CAD, coronary artery disease; DIC, disseminated intravascular coagulation; GI, gastrointestinal; INR, international.

Algorithm for the management of aortic valve stenosis

Hypothetical distribution of test results for healthy and diseased individuals. The position of the "cutoff point" between "normal" and "abnormal" (or.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Major recommendation for statin therapy for ASCVD prevention

Radiographs of the right femur in a patient with juvenile Paget disease before (left) and after (right) 10 months of treatment with calcitonin. Note the.

Diagnostic approach: anemia

Technique of varicose vein stripping

Scaphoid fracture. A. Scaphoid fracture nonunion. B

Source: Dizziness, Symptom to Diagnosis: An Evidence-Based Guide, 3e

In diastolic dysfunction, the diastolic pressure-volume relationship is shifted upward and to the left (dashed line), which leads to an elevated left ventricular.

Symptoms of alcohol withdrawal (Virtual Naval Hospital

2013 ACC/AHA cholesterol treatment guidelines

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Management of asthma exacerbation

Bieri Faces Pain Scale, revised

Approach to diagnosing pancreatic cancer

The Canadian Hypertension Education Program expedited assessment and diagnosis of patients with hypertension: Focus on validated technologies for blood.

Kaplan-Meier survival for adult heart transplants performed between January 1982 and June 2006 by era. All comparisons are significant at p < (Reproduced.

Extension of survival in months for various subgroups of patients with chronic stable angina treated by surgery as compared with those treated by medicine.

(Reproduced, with permission, from Emiliano Chavira, MD.)

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Pravastatin in Elderly Individuals at Risk of Vascular Disease

AAA, abdominal aortic aneurysm; ABIs, ankle-brachial index; GI, gastrointestinal; GU, genitourinary; MRI, magnetic resonance imaging; PAD, peripheral arterial.

Adapted with permission from Hsia, J et al

Source: Dizziness, Symptom to Diagnosis: An Evidence-Based Guide, 3e

Volume 388, Issue 10059, Pages (November 2016)

(Reproduced, with permission, from Fulop M, et al

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

HDL cholesterol and cardiovascular risk

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Volume 388, Issue 10059, Pages (November 2016)

Baseline characteristics of HPS participants by prior diabetes

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

2013 ACC/AHA cholesterol treatment guidelines

Potential mechanisms whereby statins may reduce the risk of stroke

Volume 376, Issue 9753, Pages (November 2010)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Cause of death Treatment-arm events, % (n=45 054)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

PROSPER: trial design

LDL-c reductions below 1

Presentation transcript:

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular deaths. Lifetable estimates using major vascular event risk or vascular death risk in the respective risk categories and overall treatment effects per 1.0 mmol/L reduction in LDL cholesterol with statin (1 mmol/L = 38 mg/dL). Reproduced, with permission from Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581–90. Source: Hypertension, Symptom to Diagnosis: An Evidence-Based Guide, 3e Citation: Stern SC, Cifu AS, Altkorn D. Symptom to Diagnosis: An Evidence-Based Guide, 3e; 2014 Available at: https://accessmedicine.mhmedical.com/DownloadImage.aspx?image=/data/Books/1088/ste_ch23_f001.png&sec=61699408&BookID=1088&ChapterSecID=61699379&imagename= Accessed: October 30, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved